Quest PharmaTech Inc.

51 articles about Quest PharmaTech Inc.

• OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.

  3/13/2020

  Consideration is U.S.$10 million in Cash and U.S.$40 million in a Convertible Bond

• Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.

  11/28/2018

  Agreement to develop and commercialize the Company's Targeted Cancer Therapy Technology in the U.S.

• Acerus Appoints Mr. Mark Lievonen to Its Board of Directors

  12/7/2017

  The appointment fills the vacancy resulting from Mr. Tom Rossi’s resignation from the Board of Directors.

• Quest PharmaTech Inc. Expands Its Consumer Health Product Pipeline With Clinically Validated Natural Allergy Relief

  5/4/2017

• Quest PharmaTech Inc. Retains Haft Group For Financial Services

  9/6/2016

• Quest PharmaTech Inc.'s Subsidiary, OncoQuest, Signs Agreement With Shenzhen Hepalink Pharmaceutical Co., Ltd. To Fund Immunotherapy For Treatment Of Cancer In China

  3/22/2016

• Quest PharmaTech Inc. Receives U.S. $2 Million For Its Immuno-Photodynamic Therapy Assets

  12/10/2015

• Quest PharmaTech Inc.'s Subsidiary, OncoQuest, Closes U.S. $13,000,000 Preferred Share Private Placement With Hepalink USA To Fund Immunotherapy For Treatment Of Cancer

  11/18/2015

• Quest PharmaTech Inc. Closes $1,000,000 Private Placement

  7/28/2015

• Quest PharmaTech Inc. Announces Funding Support From National Research Council's Industrial Research Assistance Program For Ige Antibody Cancer Immunotherapy Development (Allergooncology)

  1/13/2015

• Quest PharmaTech Inc. Completes Patient Enrollment In Phase 2b Study Of Oregovomab For The Immunotherapy Of Ovarian Cancer

  6/10/2014

• Q&A Interview With CEO Of Quest PharmaTech Inc. (TSX.V: QPT)

  1/22/2014

• Quest PharmaTech Inc. Strengthens its Antibody Immunotherapy Technology by Licensing Anti-Muc1 IGE Technology From Stanford University; Researchers to Present Late-Breaking Data at the 28th Annual Meeting of the Society For Immunotherapy of Cancer to be H

  11/7/2013

• Quest PharmaTech Inc. Establishes Joint Venture With Korean-Based AD Biotech Co., Ltd. to Develop Immunotherapeutic Products for Cancer

  7/23/2013

• Quest PharmaTech Inc. Signs Exclusive License Agreement With University of California, Los Angeles (UCLA) for Anti - PSA IgE Technology; UCLA researchers to Present Anti - PSA IgE Preclinical Data at the 2013 American Association for Cancer Research Confe

  4/9/2013

• Quest PharmaTech Inc. Enrolls 40th Patient in its Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial for Ovarian Cancer in Italy and the U.S.

  1/22/2013

• Quest PharmaTech Inc. Updates Progress of Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in Italy

  7/10/2012

• Quest PharmaTech Inc. Initiates Phase II Oregovomab Front-Line Chemo-Immunotherapy Clinical Trial in United States

  6/14/2012

• Quest PharmaTech Inc. Announces Signing of $8,000,000 Investment Agreement to Support Oregovomab Clinical Trial Programs

  6/6/2012

• Quest PharmaTech Inc. Announces Development of Second Generation Photodynamic Therapy Products for the Treatment of Cancer based on Nanotechnology

  11/29/2011